需求文獻(xiàn)：
1、DAWSON PA， KARPEN SJ． Bile acids reach out to the spinal cord： new insights to the
pathogenesis of itch and analgesia in cholestatic liver disease ［J］． Hepatology， 2014，
59 （4）：1638－1641．
2、Kremer AE, van Dijk R, Leckie P, et al. Serum autotaxin is increased in pruirtus of
cholestasis, but not of other oirgin, and responds to therapeutic interventions[J].
Hepatology, 2012(56): 1391-1400.
3、Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment
of primary biliary cholangitis. Sumeyye Samur,Matthew Klebanoff,Reiner Banken,Daniel S.
Pratt. 《Hepatology》 , 2017 , 65 (3) :920.
4、Obeticholic acid for PBC. Hugh Thomas. Nature Reviews Gastroenterology & Hepatology 13,
558-559 (2016).
5、Emerging and future therapies for nonalcoholic steatohepatitis in adults. Gesthimani
Mintziori , Stergios A. Polyzos. 《Expert Opinion on Pharmacotherapy》 , 2016 , 17 (14) :1
-10.
6、9、Obeticholic acid for the treatment of primary biliary cirrhosis. Trivedi PJ,
Hirschfield GM, Gershwin ME. Expert Rev Clin Pharmacol. 2016;9(1):13-26.
doi:10.1586/17512433.2015.1092381. Epub 2015 Nov 7.
7、Kowdley K，Nevens F，Andreone P，et al． The first new trials for primary biliary
cirrhosis in a decade: an international program evaluating the farnesoid X receptor agonist
obeticholic acid［J］． Gastroenterology，2015，1481 ( 4) : S991-S992．
8、Treatment of Non-Alcoholic Fatty Liver Disease . Scherer A., Dufour J.-F.
9、Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. Pencek R,
Marmon T, Roth JD, Liberman A, Hooshmand-Rad R, Young MA. Diabetes Obes Metab. 2016 Sep;18
(9):936-40. doi: 10.1111/dom.12681. Epub 2016 Jun 6.
10、Metabolite profiling of CHO?cells with different growth characteristic
11、Sun, Zhaoyun; Peng, Xinhua; Dong, Xiongzi; Shi, Wenwen - Asian Journal of Chemistry,
2012, vol. 24, # 2, p. 929 - 930
要求：下載符合需求的文獻(xiàn)PDF格式打包上傳
[更多]
渝公網(wǎng)安備 50010802001068號
